Early Detection Research Network


This biomarker is also known as:
  • melanoma-associated antigen 6,
  • MAGE3B antigen,
  • MAGE6,
  • Cancer/testis antigen 1.6,
  • CT1.6,
  • cancer/testis antigen family 1, member 6,
  • melanoma antigen family A, 6,
  • MAGE3B,
  • MAGE-6 antigen,
  • cancer/testis antigen 1.6,
  • MAGE-3b,
  • MAGEA6,


The members of the MAGEA protein family display 50-80% sequence identity among their members. MAGEA proteins are thought to play a role in tumor transformation or aspects of tumor progression. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. Alternative splicing results in multiple transcript variants.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MAGEA6 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.